Halozyme Therapeutics Inc. (HALO) exhibits 83.6% gross margins and 18.0% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 35.6x enterprise multiple and 4.8% implied options volatility.
Sustained 83.6% gross profitability converts into 33.6% operating margin and 18.0% ROIC, outpacing sector cost of capital.
ROIC: 18.0% // GM: 83.6%YoY revenue trajectory of +37.6% paired with 4.33% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +37.6% // FCF YLD: 4.33%Altman Z-Score of 5.11 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 5.11 // F-SCORE: 7/9Trading at 47.0x trailing P/E (39.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 47.0x // EV/EBITDA: 35.6xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $130.91 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 22.7% net margins.
NET MARGIN: 22.7% // D/E: 8.50x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for HALO & activate live FRED threshold breach alerts.